Changing trends in U.S. prostate cancer incidence rates

Journal of the National Cancer Institute

Volumn 88, Issue 22, 1996, Pages 1683-1685

  Merrill, Ray M ^a,b   Potosky, Arnold L ^a   Feuer, Eric J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CAUCASIAN; HUMAN; MAJOR CLINICAL STUDY; MALE; NEGRO; PROSTATE CANCER; RACE DIFFERENCE; UNITED STATES;

AFRICAN AMERICANS; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MORBIDITY; PROSTATIC NEOPLASMS; SEER PROGRAM; UNITED STATES;

EID: 0029806552     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/88.22.1683     Document Type: Article

References (15)

1. Kosary CL, Ries LA, Miller BA, Hankey BF, Harras A, Edwards BK, editors. SEER cancer statistics review, 1973-1992: tables and graphs. Bethesda (MD): National Institutes of Health, National Cancer Institute; 1995 DHHS Publ No. (NIH)96-2789.
2. Potosky AL, Miller BA, Albertsen PC, Kramer BS. The role of increasing detection in the rising incidence of prostate cancer. JAMA 1995;273:548-52.
3. Gilliland FD, Welsh DJ, Hoffman RM, Key CR. Rapid rise and subsequent decline in prostate cancer incidence rates for New Mexico, 1989-1993. Cancer Epidemiol Biomarkers Prev 1995;4:797-800.
4. Stephenson RA, Smart CR, Mineau GP, James BC, Janerich DT, Dibble RL. The fall in incidence of prostate carcinoma. On the down side of prostate specific antigen induced peak in incidence - data from the Utah Cancer Registry. Cancer 1995,77:1342-8.
5. Stanford JL, Wicklund KG, Blumenstein BA, Brawer MK. The changing epidemiology of prostate cancer in Seattle-Puget Sound region, 1974-1993. J Urol 1995;153: 504A.
6. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer [published erratum appears in N Engl J Med 1991;325:1324]. N Engl J Med 1991;324: 1156-61.
7. Catalona WJ, Smith DS, Ratliff TL, Basler JW. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening [see comment citation in Medline]. JAMA 1993;270:948-54.
8. Wynder EL, Maabuchi K, Whitmore WF. Epidemiology of cancer of the prostate. Cancer 1971;28:344-60.
9. Hinman F Jr. Screening for prostatic carcinoma.J Urol 1991;145:126-30.
10. Kramer BS, Brown ML, Prorok PC, Potosky AL, Gohagan JK. Prostate cancer screening: what we know and what we need to know [see comment citations in Medline]. Ann Intern Med 1993;119:914-23.
11. Optenberg SA, Thompson IM. Economics of screening for carcinoma of the prostate. Urol Clin North Am 1990;17:719-37.
12. Chodak G. Prostate cancer: to screen or not to screen. Acta Oncol 1991;30:285-7.
13. Lu-Yao GL, McLerran D, Wasson J, Wennberg JE. An assessment of radical prostatectomy. Time trends, geographic variation, and outcomes. The Prostate Patient Outcomes Research Team [see comment citations in Medline]. JAMA 1993;269:2633-6.
14. Fleming C, Wasson JH, Albertson PC, Barry MJ, Wennberg JE. A decision analysis of alternative treatment strategies for clinically localized prostate cancer. The Prostate Patient Outcomes Research Team [see comment citations in Medline]. JAMA 1993; 269:2650-8.
15. Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer [see comment citations in Medline]. JAMA 1995;273:289-94.